NCT05929235
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05929235
Title A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Flare Therapeutics Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California 94158 United States Details
Yale Cancer Center New Haven Connecticut 06519 United States Details
Sylvester Comprehensive Cancer Center, University of Miami Miami Florida 33136 United States Details
The University of Chicago Medicine Chicago Illinois 60637 United States Details
Mass General Cancer Center Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Icahn School of Medicine at Mount Sinai New York New York 10029 United States Details
Memorial Slone Kettering Cancer Center New York New York 10065 United States Details
UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27514 United States Details
The Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
Houston Methodist Cockrell Center for Advanced Therapeutics Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field